Edition:
United States

Eli Lilly and Co (LLY)

LLY on New York Consolidated

117.52USD
23 Jan 2019
Change (% chg)

$0.43 (+0.37%)
Prev Close
$117.09
Open
$117.11
Day's High
$118.74
Day's Low
$116.92
Volume
1,363,849
Avg. Vol
4,790,356
52-wk High
$119.84
52-wk Low
$73.69

Chart for

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $95,874.12
Shares Outstanding(Mil.): 1,100.99
Dividend: 0.52
Yield (%): 2.39

Financials

  LLY Industry Sector
P/E (TTM): 37.74 30.49 33.71
EPS (TTM): 2.31 -- --
ROI: 8.49 14.98 14.48
ROE: 17.03 16.30 15.99

S.Korean stocks, won rise on relief over trade talks; China to step up stimulus

SEOUL, Jan 23 Round-up of South Korean financial markets:

2:26am EST

Lilly cancer drug fails key trial, will no longer be prescribed

Eli Lilly and Co said on Friday that its cancer treatment Lartruvo, which had won conditional approval, failed to improve patient survival in a long-term confirmatory study and will no longer be prescribed, driving the drugmaker's shares down nearly 3 percent.

Jan 18 2019

Lilly's cancer therapy Lartruvo fails to meet main goal in late-stage trial

Jan 18 Eli Lilly and Co said on Friday its cancer treatment Lartruvo failed to meet the main goal in a late-stage trial testing the therapy in patients with advanced or metastatic soft tissue sarcoma.

Jan 18 2019

Deals of the day-Mergers and acquisitions

Jan 11 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday: ** Twenty-First Century Fox said it does not plan to bid for any of the regional sports networks that Walt Disney Co may need to sell to win U.S. Justice Department's approval for its purchase of Fox's film and TV assets. ** Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sideli

Jan 11 2019

Healthcare deals raise pulse of US lending in 2019

NEW YORK, Jan 11 (LPC) - Bankers are diagnosing another robust year for US healthcare lending. The first two big loans of 2019 are financing the acquisitions of pharmaceutical companies, including the largest ever tie-up in the sector, and more are expected.

Jan 11 2019

Eli Lilly to cut 250 jobs at France plant, through voluntary redundancy

PARIS Pharmaceutical group Eli Lilly said on Tuesday it will cut 250 jobs at its factory located near Strasbourg in Eastern France.

Jan 08 2019

Eli Lilly to cut 250 jobs at France plant, through voluntary redundancy

PARIS, Jan 8 Pharmaceutical group Eli Lilly said on Tuesday it will cut 250 jobs at its factory located near Strasbourg in Eastern France.

Jan 08 2019

Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy

Eli Lilly said on Monday it will buy Loxo Oncology Inc for $8 billion, an expensive bet on a pipeline of cancer drugs that target rare genetic mutations and the biggest acquisition in the drugmaker's 143-year history. The price represents a 68 percent premium to Loxo's Friday share price close, which some Wall Street analysts said was high for a company with only one drug on the market that it shares with a partner. | Video

Jan 07 2019

Deals of the day-Mergers and acquisitions

Jan 7 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Monday:

Jan 07 2019

Lilly to buy Loxo Oncology for about $8 bln

Jan 7 Eli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 billion in cash.

Jan 07 2019

Earnings vs. Estimates